Imdelltra significantly improves survival in SCLC patients post-platinum chemotherapy, meeting primary endpoints in the DeLLphi-304 trial. As a BiTE immunotherapy, Imdelltra enhances T cell-cancer ...

The addition of consolidative thoracic radiotherapy to chemoimmunotherapy is associated with improved survival among patients with extensive-stage small cell lung cancer.

Results showed tarlatamab significantly reduced the risk of death by 40% vs standard of care treatment (HR, 0.60 [95% CI, 0.47-0.77]; P .001). The Food and Drug Administration (FDA) has granted ...

PD-1 and PD-L1 inhibitors combined with chemotherapy significantly improve survival in ES-SCLC compared with chemotherapy alone. No significant difference in overall survival or progression-free ...

– 46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options – – First Phase III ...

Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...

Please provide your email address to receive an email when new articles are posted on . The addition of lurbinectedin to atezolizumab extended PFS and OS. A higher percentage of patients assigned the ...

An objective response rate of 48.2% was observed with ifinatamab deruxtecan in these previously treated patients Discussions with global regulatory authorities underway SCLC is aggressive and ...

PD-L1xVEGF-A bispecific antibody pumitamig (BNT327/BMS986545) plus chemotherapy continues to show encouraging antitumor activity in patients with extensive-stage small cell lung cancer (”ES-SCLC”), ...

Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier ...